A Randomized Double Blind Placebo Controlled Crossover Trial of the Use of Subcutaneous Lidocaine Infusion (SCLI) for Chronic Cancer-related Pain
This study's primary objective is to test the hypothesis that a single infusion of
subcutaneous lidocaine can cause a clinically useful reduction in cancer pain within 48
hours of infusion and lasting a minimum of 7 days. Subjects will receive either lidocaine or
placebo, followed at least 3 weeks later by the alternate agent.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society